Literature DB >> 12384913

Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.

Ori Elkayam1, Philip N Hawkins, Helen Lachmann, Michael Yaron, Dan Caspi.   

Abstract

We describe herein a patient with rheumatoid arthritis who developed proteinuria due to AA amyloidosis, in whom the inflammatory disease was rapidly and completely suppressed by treatment with infliximab. This response was accompanied by resolution of the proteinuria and stabilization of the amyloid deposits as seen on serial (123)I-labeled serum amyloid P scintigraphy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384913     DOI: 10.1002/art.10581

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  Methotrexate for rheumatoid arthritis patients who are on hemodialysis.

Authors:  Hasanein Al-Hasani; Euthalia Roussou
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

2.  Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor.

Authors:  M M Boscá; C M Pérez-Baylach; M A Solis; R Antón; E Mayordomo; S Pons; M Mínguez; A Benages
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 4.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Authors:  Tadashi Nakamura; Syu-ichi Higashi; Kunihiko Tomoda; Michishi Tsukano; Masahiro Shono
Journal:  Clin Rheumatol       Date:  2010-05-05       Impact factor: 2.980

Review 6.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

7.  A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab.

Authors:  Takeshi Kuroda; Yasuhiro Otaki; Hiroe Sato; Takeo Fujimura; Takeshi Nakatsue; Syuichi Murakami; Minoru Sakatsume; Masaaki Nakano; Fumitake Gejyo
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

8.  A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept.

Authors:  Wataru Ishii; Dai Kishida; Ayako Suzuki; Yasuhiro Shimojima; Masayuki Matsuda; Yoshinobu Hoshii; Shu-Ichi Ikeda
Journal:  Rheumatol Int       Date:  2009-10-10       Impact factor: 2.631

9.  Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.

Authors:  Hiroe Sato; Takehito Sakai; Toshiaki Sugaya; Yasuhiro Otaki; Kana Aoki; Katsushi Ishii; Hidehiro Horizono; Hiroshi Otani; Asami Abe; Noboru Yamada; Hajime Ishikawa; Kiyoshi Nakazono; Akira Murasawa; Fumitake Gejyo
Journal:  Clin Rheumatol       Date:  2009-05-13       Impact factor: 2.980

10.  Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.

Authors:  Senol Kobak; Fahrettin Oksel; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Clin Rheumatol       Date:  2007-07-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.